miR-7975对口腔鳞状细胞癌恶性表型的影响

doi:10.13591/j.cnki.kqyx.2025.07.003

Abstract

Abstract:

Objective To investigate the effect of miR-7975 on the malignant phenotype of oral squamous cell carcinoma (OSCC) and its potential mechanisms. Methods This study compared the expression levels of miR-7975 in different oral cell lines by qRT-PCR. miR-7975 mimic and miR-7975 inhibitor were transfected into OSCC cell lines HSC3 and HN4 respectively. Colony formation assay, CCK8 assay, Transwell assay, and wound healing assay were conducted to evaluate the effects of miR-7975 on the malignant phenotype of OSCC cells. Western blot was employed to analyze changes in the expression of EMT related proteins and proteins associated with the RAS/ERK signaling pathway. Subcutaneous tumor model of nude mice was used to further validate the tumorigenic effect of miR-7975 in vivo. Results The expression of miR-7975 was downregulated in OSCC cells. Overexpression of miR-7975 reduced the proliferation, migration, and invasion abilities of OSCC cells, whereas downregulation of miR-7975 enhanced these abilities. After miR-7975 overexpression, the expression of the EMT-related protein E-cadherin was upregulated, while N-cadherin, Vimentin, β-catenin, Snail, and Slug were downregulated. Additionally, the expression of proteins related to the RAS/ERK signaling pathway increased. Conversely, the expression of EMT and RAS/ERK signaling pathway-related proteins showed opposite changes when miR-7975 was downregulated. Compared to the control group, the volume and weight of tumors formed in nude mice were significantly smaller after miR-7975 overexpression, while they were significantly larger when miR-7975 expression was reduced. Conclusion miR-7975 exerts its tumor-suppressive effects by inhibiting the proliferation, migration, and invasion of OSCC through the regulation of EMT and the RAS/ERK signaling pathway.

Key words: oral squamous cell carcinoma, miR-7975, epithelial-mesenchymal transition, RAS/ERK signaling pathway

CLC Number:

R739.85

GAO Teng, ZHAO Zhenyuan, ZHAO Mengran, LIU Jie, SONG Xiaomeng. The effect of miR-7975 on the malignant phenotype of oral squamous cell carcinoma[J]. Stomatology, 2025, 45(7): 495-501.

Figures/Tables 7

Fig.1

Fig.2

Fig.3

Fig.4

Fig.5

Fig.6

Fig.7

References 26

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2]	D'Souza S, Addepalli V. Preventive measures in oral cancer: An overview[J]. Biomed Pharmacother, 2018, 107: 72-80. doi: S0753-3322(18)33634-5 pmid: 30081204
[3]	Chattopadhyay I, Verma M, Panda M. Role of oral microbiome signatures in diagnosis and prognosis of oral cancer[J]. Technol Cancer Res Treat, 2019, 18: 1533033819867354.
[4]	Struckmeier AK, Buchbender M, Lutz R, et al. Improved recurrence rates and progression-free survival in primarily surgically treated oral squamous cell carcinoma-results from a German tertiary medical center[J]. Clin Oral Investig, 2024, 28(5): 262.
[5]	Lu TX, Rothenberg ME. microRNA[J]. J Allergy Clin Immunol, 2018, 141(4): 1202-1207. doi: S0091-6749(17)31593-2 pmid: 29074454
[6]	Boehm M, Slack FJ. microRNA control of lifespan and metabolism[J]. Cell Cycle, 2006, 5(8): 837-840. doi: 10.4161/cc.5.8.2688 pmid: 16627994
[7]	Carleton M, Cleary MA, Linsley PS. microRNAs and cell cycle regulation[J]. Cell Cycle, 2007, 6(17): 2127-2132. doi: 10.4161/cc.6.17.4641 pmid: 17786041
[8]	Adereh A, Amini P, Fateh A, et al. Loc646329 sponges miR-21 to reduce RAS/MAP kinase signaling pathway in oral squamous cell carcinoma (OSCC)[J/OL]. Naunyn Schmiedeberg’s Arch Pharmacol, 2024[2025-03-03].https://doi.org/10.1007/s00210-024-03671-x.
[9]	Huang F, Xin C, Lei KX, et al. Noncoding RNAs in oral premalignant disorders and oral squamous cell carcinoma[J]. Cell Oncol (Dordr), 2020, 43(5): 763-777. doi: 10.1007/s13402-020-00521-9 pmid: 32495292
[10]	Shi BX, Ma C, Liu GL, et al. miR-106a directly targets LIMK1 to inhibit proliferation and EMT of oral carcinoma cells[J]. Cell Mol Biol Lett, 2019, 24: 1. doi: 10.1186/s11658-018-0127-8 pmid: 30873211
[11]	Zheng Y, Song A, Zhou Y, et al. Identification of extracellular vesicles-transported miRNAs in Erlotinib-resistant head and neck squamous cell carcinoma[J]. J Cell Commun Signal, 2020, 14(4): 389-402.
[12]	de Rooij LA, Mastebroek DJ, Ten Voorde N, et al. The microRNA lifecycle in health and cancer[J]. Cancers (Basel), 2022, 14(23): 5748.
[13]	Rishabh K, Khadilkar S, Kumar A, et al. microRNAs as modulators of oral tumorigenesis-a focused review[J]. Int J Mol Sci, 2021, 22(5): 2561.
[14]	Y D, Ramani P, Yuwanati M, et al. microRNA profiling in circulating exosomes in oral squamous cell carcinoma: A systematic review[J]. Cureus, 2023, 15(8): e43235.
[15]	Yoon AJ, Wang S, Kutler DI, et al. microRNA-based risk scoring system to identify early-stage oral squamous cell carcinoma patients at high-risk for cancer-specific mortality[J]. Head Neck, 2020, 42(8): 1699-1712.
[16]	Li YI, Wang TY, Ding HR, et al. Exosomal microRNA let-7c-5p enhances cell malignant characteristics by inhibiting TAGLN in oral cancer[J]. Oncol Res, 2024, 32(10): 1623-1635. doi: 10.32604/or.2024.048191 pmid: 39308508
[17]	Chen YM, Wang YC, Zhang WB. LINC00342 regulates the PI3K-AKT signaling pathway via the miR-149-5p/FGF11 axis and affects the progression of oral cancer[J]. Discov Oncol, 2024, 15(1): 606.
[18]	Pan ZY, Yang GZ, He H, et al. Identification of cerebrospinal fluid microRNAs associated with leptomeningeal metastasis from lung adenocarcinoma[J]. Front Oncol, 2020, 10: 387. doi: 10.3389/fonc.2020.00387 pmid: 32328453
[19]	Karere GM, Glenn JP, Li G, et al. Potential miRNA biomarkers and therapeutic targets for early atherosclerotic lesions[J]. Sci Rep, 2023, 13: 3467. doi: 10.1038/s41598-023-29074-1 pmid: 36859458
[20]	Lee JH, Massagué J. TGF-β in developmental and fibrogenic EMTs[J]. Semin Cancer Biol, 2022, 86: 136-145. doi: 10.1016/j.semcancer.2022.09.004 pmid: 36183999
[21]	Li X, Chen L, Peng X, et al. Progress of tumor-associated macrophages in the epithelial-mesenchymal transition of tumor[J]. Front Oncol, 2022, 12: 911410.
[22]	Zhang Y, Donaher JL, Das S, et al. Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis[J]. Nat Cell Biol, 2022, 24: 554-564. doi: 10.1038/s41556-022-00877-0 pmid: 35411083
[23]	Ebrahimi N, Manavi MS, Faghihkhorasani F, et al. Harnessing function of EMT in cancer drug resistance: A metastasis regulator determines chemotherapy response[J]. Cancer Metastasis Rev, 2024, 43(1): 457-479.
[24]	Li YX, Li B, Yang K, et al. PER3 suppresses tumor metastasis of oral squamous cell carcinoma by promoting HIF-1α degradation[J]. Transl Oncol, 2025, 52: 102258.
[25]	Dillon M, Lopez A, Lin E, et al. Progress on ras/MAPK signaling research and targeting in blood and solid cancers[J]. Cancers (Basel), 2021, 13(20): 5059.
[26]	Bugaj LJ, Sabnis AJ, Mitchell A, et al. Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway[J]. Science, 2018, 361(6405): eaao3048.

The effect of miR-7975 on the malignant phenotype of oral squamous cell carcinoma

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 26

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHOU Xing’an, DELEHEI Bateer, WU Xu, MA Hongyu, XIA Fengjun, SHEN Tiebing, SHANG Duo. Research progress of tumor-derived exosomes in oral squamous cell carcinoma [J]. Stomatology, 2025, 45(6): 465-469.
[2]	CHEN Yue, SUN Xueqian, CHEN Minmin. Research progress of lncRNA UCA1 in oral squamous cell carcinoma [J]. Stomatology, 2025, 45(4): 317-320.
[3]	XIONG Ke, ZHANG Hao, HU Tuqiang. Experimental study on emodin regulating the proliferation of oral squamous cell carcinoma cells through autophagy [J]. Stomatology, 2024, 44(8): 602-608.
[4]	YI Jie, DING Yujie, SHAN Yufei, GU Jiaqi, SUN Zhida. Neutrophil extracellular traps regulating the development and prognosis of oral squamous cell carcinomas [J]. Stomatology, 2024, 44(7): 500-517.
[5]	SUN Xinyi, PAN Yuetong, LU Xinyue, LYU Zhongjing, YUAN Jian, LI Jiafeng, SHI Huan. Analysis of PTK7 expression in oral squamous cell carcinoma and its biological function [J]. Stomatology, 2024, 44(4): 268-275.
[6]	WANG Yapei, LUO Yuchun, LIU Wei, LIU Chang, TANG Wanrong. Effect of EP300 on the proliferation and migration of oral squamous carcinoma cells [J]. Stomatology, 2024, 44(2): 88-93.
[7]	YAO Tian, MA Yufeng. Research progress of cuproptosis in the treatment and prognosis of oral squamous cell carcinoma [J]. Stomatology, 2024, 44(11): 871-875.
[8]	HU Haiyan, GAO Teng, ZHU Zai'ou, DING Xu, WU Yunong, SONG Xiaomeng. Study on the role of CMTM4 in oral squamous cell carcinoma and its mechanism [J]. Stomatology, 2023, 43(6): 481-487.
[9]	XU Yiping, HUANG Jialing, LIU Zhongbin, YANG Kun, GE Song. Research progress of the relationship between Fusobacterium nucleatum and oral squamous cell carcinoma [J]. Stomatology, 2023, 43(6): 546-551.
[10]	YANG Yuemei,SONG Xiaomeng,WU Yunong. Promotion of cell proliferation by Notch1^P1641S mutation through PI3K/Akt activation in OSCC [J]. Stomatology, 2023, 43(5): 393-399.
[11]	XIAO Tao, HE Yijia, ZHU Yaoping, HAO Fengyao, CHEN Yan, WANG Zhiyong. Study on the mechanism of VEGF inducing tolerogenic dendritic cells in oral squamous cell carcinoma [J]. Stomatology, 2023, 43(3): 204-211.
[12]	TONG Xuexi, ZHAO Gang. In vitro study on miR-191-5p targeting TJP1 to regulate the proliferation, invasion and migration of Cal-27 cells [J]. Stomatology, 2023, 43(11): 981-988.
[13]	XIAO Jinzhi, YU Wei, ZHANG Hao. Berberine hydrochloride inhibits the proliferation of oral squamous cell carcinoma by regulating autophagy [J]. Stomatology, 2023, 43(10): 889-893.
[14]	MA Ping, CHENG Luyao, JIN Wulong, WANG Ning, ZHAI Rongping. Expression level and biological function of NCAPD2 in oral squamous cell carcinoma [J]. Stomatology, 2022, 42(8): 688-693.
[15]	WANG Jinxin, YI Jie, DING Yujie, ZHONG Yi, SUN Zhida. Expression and role of Claudin-7 in oral squamous cell carcinoma [J]. Stomatology, 2022, 42(7): 604-608.